Alignment Healthcare (ALHC) Q3 2023: 27% Revenue Growth Underscores Stars Funding Advantage

2023-11-02 | By EarningsIQ Research

Alignment Healthcare delivered 27% year-over-year revenue growth in Q3, outpacing expectations on membership, profit, and operational discipline. Strategic investments in product innovation and provider engagement are translating into outsized Stars performance, setting the stage for a funding and growth advantage into 2024. Leadership’s confidence in break-even EBITDA next year is grounded in both quality execution and favorable industry dynamics.

Summary

• Stars Ratings Outperformance: Alignment’s high Stars penetration secures a funding edge as rivals face rating declines.
• Product and Provider Innovation: New benefit partnerships and clinical models drive member retention and acquisition.
• 2024 Growth Visibility: Early AEP results and raised guidance reinforce confidence in 20%+ membership growth next year.

Business Overview

Alignment Healthcare is a technology-enabled Medicare Advantage (MA, private Medicare plans) insurer focused on seniors, operating primarily in California with expansion in North Carolina and Nevada. The company generates revenue through monthly premiums paid by Medicare, adjusted for risk and quality (Stars ratings), and delivers care via a member-first model integrating clinical programs, provider partnerships, and digital tools. Its business is organized around health plan membership, with additional exposure to ACO REACH (Accountable Care Organization Realizing Equity, Access, and Community Health, a value-based Medicare program) and a growing suite of supplemental benefits.

Performance Analysis

Alignment posted Q3 revenue of $456.7 million, up 27% year-over-year, and grew health plan membership 18% to 115,600. This outperformance was driven by both strong new sales and improved retention, reflecting investments in sales infrastructure and member experience. Adjusted gross profit reached $60.6 million, with a consolidated medical benefit ratio (MBR, percentage of premiums spent on care) of 86.7%, and adjusted EBITDA loss narrowed to $8.4 million, ahead of guidance.

SG&A discipline was evident as expenses excluding equity compensation rose 19% year-over-year, but fell as a percent of revenue by 100 basis points. The company ended the quarter with $515.6 million in cash and short-term investments, though this figure includes a $146.3 million early CMS payment, highlighting a strong liquidity position. Stars performance remains a critical differentiator: 92% of members are in plans rated four stars or higher for 2024, compared to a sector-wide drop to 55% in California.

• Membership Growth Momentum: Intra-year net adds and improved retention drove the membership beat, with California remaining the core growth engine.
• Operational Efficiency: Stable utilization trends and clinical program engagement kept inpatient admissions per thousand in the low 150s for a second consecutive quarter.
• Stars-Driven Funding: Stars outperformance underpins benefit richness and competitive positioning as rivals face funding headwinds.

Leadership raised full-year guidance for both membership and revenue, now targeting 20% and 24.8% growth, respectively, at the midpoint, and reiterated an adjusted EBITDA break-even target for 2024.

Executive Commentary

Strategic Positioning

1. Stars Ratings as a Funding Moat

Alignment’s 92% four-star-or-better coverage delivers a material funding advantage as competitors in California face steep declines in Stars bonuses, impacting their ability to fund benefits. This quality-driven differentiation supports both member retention and new sales, and is expected to persist into 2025 as new CMS risk adjustment (V28) and Stars methodologies phase in.

2. Product Innovation and Benefit Design

Alignment leverages its Stars-driven revenue to enhance benefit richness, as seen in expanded dental, lower out-of-pocket maximums, and premium reductions for 95% of non-SNP (Special Needs Plan) members in 2024. Partnerships with Instacart and Walgreens introduce retail and technology convergence, positioning the company to attract diverse senior segments and improve member experience.

3. Provider Engagement and Care Model Integration

The company’s ‘Care Anywhere’ model and AVA (proprietary technology platform) underpin clinical and cost management performance, enabling stable utilization and high provider satisfaction. Alignment’s collaborative approach with IPAs (Independent Physician Associations) and direct providers is cited as a competitive advantage, especially as hospital systems reassess MA participation and seek care model partners.

4. Disciplined Expansion and Margin Pathway

Management emphasizes a balanced approach to geographic expansion, prioritizing existing market share gains while cautiously entering new counties and states. This discipline preserves margin trajectory, with SG&A leverage and operational improvements expected to drive adjusted EBITDA break-even in 2024, even as new market investments continue.

5. Broker and Distribution Strategy

Alignment’s tighter broker management and operational sales control are producing higher quality distribution, with a focus on compliance and member satisfaction. Leadership highlights a selective approach, working only with top-performing brokers to drive sustained growth and mitigate regulatory risk.

Key Considerations

This quarter’s results highlight Alignment’s ability to outperform both on growth and quality metrics, while maintaining operational discipline. The interplay of Stars funding, benefit innovation, and provider engagement is central to the company’s strategy as the MA landscape faces regulatory and competitive headwinds.

Key Considerations:

• Stars Concentration as a Double-Edged Sword: While Stars outperformance drives funding, any future slip in ratings could rapidly erode Alignment’s competitive advantage.
• New Member Mix and Margin Drag: Elevated MBR for new entrants creates short-term margin pressure, requiring continued clinical engagement ramp.
• Geographic Growth Discipline: Expansion outside California remains measured, with California as the primary engine, but new markets are critical for long-term scale.
• Retail and Tech Partnerships: Early Instacart and Walgreens collaborations signal potential for differentiated senior engagement and benefit delivery.

Risks

Alignment’s Stars-driven funding advantage is exposed to regulatory volatility and competitive catch-up, particularly as CMS continues to refine risk adjustment and Stars methodologies. New market expansion introduces margin drag and operational complexity, while rising labor costs and potential hospital contract renegotiations in California could pressure future unit costs. The ACO REACH program remains a low-margin, policy-sensitive segment, with limited near-term profit impact.

Forward Outlook

For Q4 2023, Alignment guided to:

• Health plan membership of 117,600 to 118,600
• Revenue of $422 million to $442 million
• Adjusted gross profit of $46 million to $54 million
• Adjusted EBITDA loss of $18 million to $10 million

For full-year 2023, management raised guidance:

• Revenue of $1.78 billion to $1.8 billion
• Adjusted gross profit of $206 million to $214 million
• Adjusted EBITDA loss of $34 million to $26 million

Management cited ongoing Stars and product tailwinds, continued operational discipline, and robust AEP momentum as drivers for confidence in 2024’s 20% membership growth and break-even EBITDA target.

• Stars funding and benefit design expected to support above-market growth
• Ongoing investments in clinical engagement and member experience to drive retention and utilization management

Takeaways

Alignment’s Q3 results reinforce its strategic position as a quality-driven, growth-focused MA player able to fund richer benefits and expand share in core markets.

• Stars Funding Edge: Outperformance on Stars ratings is translating into tangible product and margin advantages as competitors face headwinds.
• Operational and Distribution Discipline: Tight SG&A control, measured expansion, and selective broker partnerships underpin sustainable growth.
• 2024 Watchpoints: Investors should monitor Stars sustainability, new market ramp costs, and the impact of supplemental benefit innovation on member mix and retention.

Conclusion

Alignment Healthcare’s Q3 2023 results showcase the power of a Stars-driven MA platform with disciplined execution across growth, cost management, and benefit innovation. With a clear funding advantage and strong operational levers, the company is positioned to deliver on its break-even EBITDA and growth targets into 2024.

Industry Read-Through

Alignment’s Stars outperformance and funding advantage highlight the widening gap between quality leaders and laggards in Medicare Advantage. As the CMS Stars methodology tightens and risk adjustment models evolve, MA plans with integrated clinical models, provider partnerships, and benefit innovation are best positioned to gain share. Rivals facing Stars downgrades and unit cost inflation may be forced to cut benefits or exit markets, while regional players with strong provider engagement can capture share from national incumbents. The retail and technology convergence in supplemental benefits, as seen with Instacart and Walgreens, signals a broader industry trend toward consumer-centric design and multi-channel engagement, likely to accelerate in the next cycle.

ALHC Healthcare Managed Care Medicare Advantage Stars Ratings Benefit Innovation Provider Partnerships Membership Growth